<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Lumiracoxib</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01283</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Lumiracoxib is a <span class="caps">COX</span>-2 selective inhibitor non-steroidal anti-inflammatory drug. On August 11, 2007, Australia&#8217;s Therapeutic Goods Administration (<span class="caps">TGA</span>, the Australian equivalent of the <span class="caps">FDA</span>) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01283/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01283/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01283.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01283.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01283.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01283.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01283.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01283">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>COX 189</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Prexige</td><td>Novartis</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/cyclooxygenase-2-inhibitors">Cyclooxygenase 2 Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>220991-20-8</td></tr><tr><th>Weight</th><td>Average: 293.721<br>Monoisotopic: 293.061884577</td></tr><tr><th>Chemical Formula</th><td>C<sub>15</sub>H<sub>13</sub>ClFNO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>KHPKQFYUPIUARC-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C15H13ClFNO2/c1-9-5-6-13(10(7-9)8-14(19)20)18-15-11(16)3-2-4-12(15)17/h2-7,18H,8H2,1H3,(H,19,20)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-{2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl}acetic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1=CC=C(NC2=C(Cl)C=CC=C2F)C(CC(O)=O)=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenylacetic Acid Derivatives</td></tr><tr><th>Direct parent</th><td>Phenylacetic Acid Derivatives</td></tr><tr><th>Alternative parents</th><td>Toluenes; Chlorobenzenes; Fluorobenzenes; Aryl Chlorides; Aryl Fluorides; Enolates; Polyamines; Secondary Amines; Carboxylic Acids; Organochlorides; Organofluorides</td></tr><tr><th>Substituents</th><td>chlorobenzene; fluorobenzene; toluene; aryl chloride; aryl halide; aryl fluoride; carboxylic acid derivative; secondary amine; carboxylic acid; enolate; polyamine; organochloride; organohalogen; organofluoride; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the acute and chronic treatment of the signs and symptoms of osteoarthritis of the knee in adults.</td></tr><tr><th>Pharmacodynamics</th><td>Lumiracoxib has a different structure from the standard COX-2 inhibitors (e.g. celecoxib). It more closely resembles the structure of diclofenac (one chlorine substituted by fluorine, the phenylacetic acid has another methyl group in meta position), making it a member of the arylalkanoic acid family of NSAIDs. It binds to a different site on the COX-2 receptor than the standard COX-2 inhibitors. It displays extremely high COX-2 selectivity.</td></tr><tr><th>Mechanism of action</th><td>The mechanism of action of lumiracoxib is due to inhibition of prostaglandin synthesis via inhibition of cyclooygenase-2 (COX-2). Lumiracoxib does not inhibit COX-1 at therapeutic concentrations.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed following oral administration, with an absolute oral bioavailablity of 74%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Highly bound to plasma proteins (&gt;= 98%).</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic oxidation and hydroxylation via CYP2C9. Three major metabolites have been identified in plasma: 4'-hydroxy-lumiracoxib, 5-carboxy-lumiracoxib, and 4'-hydroxy-5-carboxy-lumiracoxib.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Lumiracoxib</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET01274">Lumiracoxib metabolite M21</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1434">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01274">Lumiracoxib metabolite M21</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01275">5-Carboxylumiracoxib (M11)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1435">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01275">5-Carboxylumiracoxib (M11)</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01276">Lumiracoxib metabolite M15</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1436">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01276">Lumiracoxib metabolite M15</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0004859" target="_blank">UDP-glucuronosyltransferase</a></li></ul></td><td><a href="/metabolites/DBMET01277">Lumiracoxib metabolite M16/17</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1437">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01275">5-Carboxylumiracoxib (M11)</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0004859" target="_blank">UDP-glucuronosyltransferase</a></li></ul></td><td><a href="/metabolites/DBMET01278">5-Carboxylumiracoxib glucuronide (M3)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1438">Details</a></td></tr><tr><td>Lumiracoxib</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0004859" target="_blank">UDP-glucuronosyltransferase</a></li></ul></td><td><a href="/metabolites/DBMET01279">Lumiracoxib glucuronide (M24)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1439">Details</a></td></tr><tr><td>Lumiracoxib</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET01280">4'-hydroxylumiracoxib (M23)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1440">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01280">4'-hydroxylumiracoxib (M23)</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0004859" target="_blank">UDP-glucuronosyltransferase</a></li></ul></td><td><a href="/metabolites/DBMET01281">4'-Carboxylumiracoxib glucuronide (M22)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1441">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01280">4'-hydroxylumiracoxib (M23)</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01282">Lumiracoxib metabolite M25</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1442">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01282">Lumiracoxib metabolite M25</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0004859" target="_blank">UDP-glucuronosyltransferase</a></li></ul></td><td><a href="/metabolites/DBMET01283">Lumiracoxib metabolite M25 glucuronide (M20)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1443">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01280">4'-hydroxylumiracoxib (M23)</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01284">Lumiracoxib metabolite M9</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1444">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01284">Lumiracoxib metabolite M9</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01285">4'-Hydroxy-5-carboxylumiracoxib (M5)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1445">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01285">4'-Hydroxy-5-carboxylumiracoxib (M5)</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0004860" target="_blank">Sulfotransferase (SULT)</a></li></ul></td><td><a href="/metabolites/DBMET01286">Lumiracoxib metabolite M2</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1446">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01285">4'-Hydroxy-5-carboxylumiracoxib (M5)</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01287">Lumiracoxib metabolite M8</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1447">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01287">Lumiracoxib metabolite M8</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01288">Lumiracoxib metabolite M4/M6</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1448">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01287">Lumiracoxib metabolite M8</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0004859" target="_blank">UDP-glucuronosyltransferase</a></li></ul></td><td><a href="/metabolites/DBMET01289">Lumiracoxib metabolite M10</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1449">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01287">Lumiracoxib metabolite M8</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01290">Hydroxylumiracoxib metabolite M8 (M12)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1450">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01290">Hydroxylumiracoxib metabolite M8 (M12)</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0004859" target="_blank">UDP-glucuronosyltransferase</a></li></ul></td><td><a href="/metabolites/DBMET01291">Lumiracoxib metabolite M12 glucuronide (M13)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1452">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01275">5-Carboxylumiracoxib (M11)</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01285">4'-Hydroxy-5-carboxylumiracoxib (M5)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1453">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01274">Lumiracoxib metabolite M21</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01284">Lumiracoxib metabolite M9</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1454">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01276">Lumiracoxib metabolite M15</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01287">Lumiracoxib metabolite M8</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1455">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>Terminal half-life is approximately 4 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Single oral doses in mice and rats resulted in mortality and/or moribundity at doses of 600 mg/kg and 500 mg/kg, respectively. Single intraperitoneal doses in mice and rats results in mortality/moribundity at 750 mg/kg and 1000 mg/kg, respectively. The maximum non-lethal single oral and intraperitoneal dose in mouse was 300 mg/kg and 250 mg/kg, respectively. In the rat it was 150 mg/kg and 250 mg/kg, respectively.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9825</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9715</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.818</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7336</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7134</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9389</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.916</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7247</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8639</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5964</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.5208</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.6844</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8163</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8576</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8063</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.6222</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8453
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6326
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9954
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.5160 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9512
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7169
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>logP</td><td>3.9</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>5.49e-03 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>4.56</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>4.31</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4.7</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>4.11</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>-1.9</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>-1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>49.33</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>75.91</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>28.53</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D03714" target="_blank">D03714 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50207446" target="_blank">50207446 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000970" target="_blank">DAP000970 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA164769031" target="_blank">PA164769031 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2288036" target="_blank">2288036 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Lumiracoxib" target="_blank">Lumiracoxib <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>M01AH06<ul class="atc-drug-tree"><li><a href="/atc/M#M">M &#8212; MUSCULO-SKELETAL SYSTEM</a></li><li><a href="/atc/M01#M01">M01 &#8212; ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS</a></li><li><a href="/atc/M01A#M01A">M01A &#8212; ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS</a></li><li><a href="/atc/M01AH#M01AH">M01AH &#8212; Coxibs</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>28:08.04.08</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Lumiracoxib may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Lumiracoxib may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Lumiracoxib may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>The COX-2 inhibitor increases serum levels of lithium</td></tr><tr><td><a href="/drugs/DB00966">Telmisartan</a></td><td>Concomitant use of Telmisartan and Lumiracoxib may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. </td></tr><tr><td><a href="/drugs/DB00373">Timolol</a></td><td>The NSAID, Lumiracoxib, may antagonize the antihypertensive effect of Timolol.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Lumiracoxib. Consider alternate therapy or monitor for changes in Lumiracoxib therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The NSAID, Lumiracoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Lumiracoxib is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Lumiracoxib. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Lumiracoxib may increase the anticoagulant effect of warfarin.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with or without food. Food has no effect on the absorption of the product.</li></ul></td></tr></tbody></table>